USPTO OK's Argentum's challenge to Novartis Afinitor patent

|About: Novartis AG (NVS)|By:, SA News Editor

The USPTO's Patent Trial and Appeal Board grants a petition from generic drug maker Argentum Pharmaceuticals for inter partes review of Novartis' (NVS +1.1%) U.S. Patent No. 9,006,224 covering AFINITOR (everolimus) after determining that Argentum would likely prevail in challenging claims 1-3 of the patent. A final decision will on patentability will be made within one year.

Subscribe for full text news in your inbox